{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:26:10Z","timestamp":1773257170406,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04045-y","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T15:54:26Z","timestamp":1741276466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhaoli","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"2","key":"4045_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","volume":"73","author":"LA Inker","year":"2019","unstructured":"Inker LA, Grams ME, Levey AS, et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data Meta-analysis in a global consortium. Am J Kidney Dis. 2019;73(2):206\u201317.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4045_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12882-020-01796-8","volume":"21","author":"NH Dinh","year":"2020","unstructured":"Dinh NH, Cheanh Beaupha SM, Tran LTA. The validity of reticulocyte hemoglobin content and percentage of hypochromic red blood cells for screening iron-deficiency anemia among patients with end-stage renal disease: a retrospective analysis. BMC Nephrol. 2020;21(1):142.","journal-title":"BMC Nephrol"},{"issue":"1","key":"4045_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88.","journal-title":"BMC Nephrol"},{"key":"4045_CR4","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portoles","year":"2021","unstructured":"Portoles J, Martin L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021;8:642296.","journal-title":"Front Med (Lausanne)"},{"key":"4045_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cca.2020.01.032","volume":"504","author":"C Ogawa","year":"2020","unstructured":"Ogawa C, Tsuchiya K, Maeda K. Reticulocyte hemoglobin content. Clin Chim Acta. 2020;504:138\u201345.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"4045_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ijlh.12013","volume":"35","author":"E Urrechaga","year":"2013","unstructured":"Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol. 2013;35(2):144\u20139.","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"4045_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ajh.21090","volume":"83","author":"AE Mast","year":"2008","unstructured":"Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol. 2008;83(4):307\u201310.","journal-title":"Am J Hematol"},{"issue":"5","key":"4045_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2257.2006.00812.x","volume":"28","author":"C Brugnara","year":"2006","unstructured":"Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient States. Clin Lab Haematol. 2006;28(5):303\u20138.","journal-title":"Clin Lab Haematol"},{"issue":"1","key":"4045_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1751-553X.2007.00901.x","volume":"30","author":"JM Kim","year":"2008","unstructured":"Kim JM, Ihm CH, Kim HJ. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients. Int J Lab Hematol. 2008;30(1):46\u201352.","journal-title":"Int J Lab Hematol"},{"key":"4045_CR10","doi-asserted-by":"crossref","unstructured":"Gelaw Y, Woldu B, Melku M. The role of reticulocyte hemoglobin content for diagnosis of Iron deficiency and Iron deficiency anemia, and monitoring of Iron therapy: a literature review. Clin Lab. 2019;65(12).","DOI":"10.7754\/Clin.Lab.2019.190315"},{"issue":"6","key":"4045_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.4103\/1319-2442.308335","volume":"31","author":"D Sany","year":"2020","unstructured":"Sany D, El Shahawi Y, Taha J. Diagnosis of iron deficiency in Hemodialysis patients: usefulness of measuring reticulocyte hemoglobin equivalent. Saudi J Kidney Dis Transpl. 2020;31(6):1263\u201372.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"4","key":"4045_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","volume":"67","author":"LE Ratcliffe","year":"2016","unstructured":"Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and management of Iron deficiency in CKD: A summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis. 2016;67(4):548\u201358.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4045_CR13","first-page":"34","volume":"49","author":"R Wirawan","year":"2017","unstructured":"Wirawan R, Tedja AT, Henrika F, Lydia A. Concordance between reticulocyte hemoglobin equivalent and reticulocyte hemoglobin content in CKD patients undergoing Hemodialysis. Acta Med Indones. 2017;49(1):34\u201340.","journal-title":"Acta Med Indones"},{"key":"4045_CR14","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.2147\/DDDT.S175887","volume":"12","author":"H Zhong","year":"2018","unstructured":"Zhong H, Zhou T, Li H, Zhong Z. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Des Devel Ther. 2018;12:3003\u201311.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"4045_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000328037","volume":"32","author":"MI Yilmaz","year":"2011","unstructured":"Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011;32(3):220\u20135.","journal-title":"Blood Purif"},{"key":"4045_CR16","doi-asserted-by":"publisher","first-page":"118203","DOI":"10.1016\/j.lfs.2020.118203","volume":"259","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Hu Z, Zeng R, Yao Y. HMGB1 in kidney diseases. Life Sci. 2020;259:118203.","journal-title":"Life Sci"},{"key":"4045_CR17","doi-asserted-by":"publisher","first-page":"616696","DOI":"10.3389\/fendo.2021.616696","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Chen X, Lv Y. HMGB1 mediated inflammation and autophagy contribute to endometriosis. Front Endocrinol (Lausanne). 2021;12:616696.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4045_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/187221412802481784","volume":"6","author":"JA Nogueira-Machado","year":"2012","unstructured":"Nogueira-Machado JA, de Oliveira Volpe CM. HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(3):201\u20139.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"issue":"15","key":"4045_CR19","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.7150\/ijbs.87964","volume":"19","author":"T Liu","year":"2023","unstructured":"Liu T, Li Q, Jin Q, et al. Targeting HMGB1: A potential therapeutic strategy for chronic kidney disease. Int J Biol Sci. 2023;19(15):5020\u201335.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"4045_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","volume":"33","author":"MA Atkinson","year":"2018","unstructured":"Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol. 2018;33(2):227\u201338.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"4045_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5935\/0101-2800.20160053","volume":"38","author":"SA Antunes","year":"2016","unstructured":"Antunes SA, Canziani ME. Hepcidin: an important iron metabolism regulator in chronic kidney disease. J Bras Nefrol. 2016;38(3):351\u201355.","journal-title":"J Bras Nefrol"},{"key":"4045_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/bs.vh.2019.01.012","volume":"110","author":"A Santos-Silva","year":"2019","unstructured":"Santos-Silva A, Ribeiro S, Reis F, Belo L. Hepcidin in chronic kidney disease anemia. Vitam Horm. 2019;110:243\u201364.","journal-title":"Vitam Horm"},{"issue":"4","key":"4045_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.ackd.2019.04.005","volume":"26","author":"AK Agarwal","year":"2019","unstructured":"Agarwal AK, Yee J, Hepcidin. Adv Chronic Kidney Dis. 2019;26(4):298\u2013305.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"4045_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting Hypoxia-Inducible factors for the treatment of Anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187\u201399.","journal-title":"Am J Nephrol"},{"issue":"10","key":"4045_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","volume":"30","author":"A Besarab","year":"2015","unstructured":"Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of Roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transpl. 2015;30(10):1665\u201373.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4045_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bcmd.2014.06.006","volume":"53","author":"G Ravasi","year":"2014","unstructured":"Ravasi G, Pelucchi S, Greni F, et al. Circulating factors are involved in hypoxia-induced Hepcidin suppression. Blood Cells Mol Dis. 2014;53(4):204\u201310.","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"4045_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI0215686","volume":"110","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide Hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037\u201344.","journal-title":"J Clin Invest"},{"issue":"4","key":"4045_CR28","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s11033-011-1182-7","volume":"39","author":"H Song","year":"2012","unstructured":"Song H, Yin D, Liu Z. GDF-15 promotes angiogenesis through modulating p53\/HIF-1alpha signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep. 2012;39(4):4017\u201322.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"4045_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","volume":"111","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble Hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008;111(2):924\u201331.","journal-title":"Blood"},{"issue":"7","key":"4045_CR30","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI31370","volume":"117","author":"C Peyssonnaux","year":"2007","unstructured":"Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117(7):1926\u201332.","journal-title":"J Clin Invest"},{"issue":"3","key":"4045_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/HJH.0000000000003623","volume":"42","author":"Y Naito","year":"2024","unstructured":"Naito Y, Yasumura S, Okuno K, et al. Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats. J Hypertens. 2024;42(3):497\u2013505.","journal-title":"J Hypertens"},{"issue":"3","key":"4045_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000495750","volume":"5","author":"C Munoz Abellan","year":"2019","unstructured":"Munoz Abellan C, Mangold-Gehring S, Micus S, et al. A novel model of chronic kidney disease in rats: dietary adenine in combination with unilateral nephrectomy. Kidney Dis (Basel). 2019;5(3):135\u201343.","journal-title":"Kidney Dis (Basel)"},{"issue":"6","key":"4045_CR33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.mayocp.2020.10.042","volume":"96","author":"M Auerbach","year":"2021","unstructured":"Auerbach M, Staffa SJ, Brugnara C. Using reticulocyte hemoglobin equivalent as a marker for Iron deficiency and responsiveness to Iron therapy. Mayo Clin Proc. 2021;96(6):1510\u201319.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"4045_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00467-015-3284-2","volume":"31","author":"S Davidkova","year":"2016","unstructured":"Davidkova S, Prestidge TD, Reed PW, Kara T, Wong W, Prestidge C. Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis. Pediatr Nephrol. 2016;31(5):819\u201326.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4045_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/jcp-2021-208077","volume":"76","author":"LX Pei","year":"2023","unstructured":"Pei LX, Kroeun H, Karakochuk CD. Reticulocyte haemoglobin equivalent (RET-He) as an early marker of responsiveness to oral iron supplementation. J Clin Pathol. 2023;76(6):407\u201312.","journal-title":"J Clin Pathol"},{"issue":"9","key":"4045_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone Hepcidin. J Clin Invest. 2004;113(9):1271\u20136.","journal-title":"J Clin Invest"},{"issue":"11","key":"4045_CR37","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1074\/jbc.M008923200","volume":"276","author":"C Pigeon","year":"2001","unstructured":"Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide Hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811\u20139.","journal-title":"J Biol Chem"},{"key":"4045_CR38","doi-asserted-by":"crossref","unstructured":"Hazin MAA. Anemia in chronic kidney disease. Rev Assoc Med Bras (1992). 2020;66Suppl 1(Suppl 1):s55\u20138.","DOI":"10.1590\/1806-9282.66.s1.55"},{"key":"4045_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fmed.2020.00393","volume":"7","author":"Z Yan","year":"2020","unstructured":"Yan Z, Xu G. A novel choice to correct Inflammation-Induced Anemia in CKD: oral Hypoxia-Inducible factor Prolyl hydroxylase inhibitor Roxadustat. Front Med (Lausanne). 2020;7:393.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"4045_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1042\/CS20171625","volume":"132","author":"Y Yang","year":"2018","unstructured":"Yang Y, Yu X, Zhang Y, et al. Hypoxia-inducible factor Prolyl hydroxylase inhibitor Roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018;132(7):825\u201338.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"4045_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2119\/molmed.2014.00014","volume":"20","author":"DS Pisetsky","year":"2014","unstructured":"Pisetsky DS. The expression of HMGB1 on microparticles released during cell activation and cell death in vitro and in vivo. Mol Med. 2014;20(1):158\u201363.","journal-title":"Mol Med"},{"issue":"11","key":"4045_CR42","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, et al. Roxadustat treatment for Anemia in patients undergoing Long-Term Dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"4045_CR43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in patients with kidney disease not receiving Dialysis. N Engl J Med. 2019;381(11):1001\u201310.","journal-title":"N Engl J Med"},{"key":"4045_CR44","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.phrs.2020.104747","volume":"155","author":"J Liu","year":"2020","unstructured":"Liu J, Zhang A, Hayden JC, et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.","journal-title":"Pharmacol Res"},{"key":"4045_CR45","doi-asserted-by":"publisher","first-page":"154873","DOI":"10.1016\/j.phymed.2023.154873","volume":"116","author":"R Li","year":"2023","unstructured":"Li R, Shi C, Wei C, et al. Fufang Shenhua tablet inhibits renal fibrosis by inhibiting PI3K\/AKT. Phytomedicine. 2023;116:154873.","journal-title":"Phytomedicine"},{"key":"4045_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","volume":"65","author":"S Djudjaj","year":"2019","unstructured":"Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med. 2019;65:16\u201336.","journal-title":"Mol Aspects Med"},{"key":"4045_CR47","doi-asserted-by":"publisher","first-page":"788977","DOI":"10.3389\/fphar.2021.788977","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, Jiang B, Zou Y, Zhang J, Fu YY, Zhai XY. Roxadustat (FG-4592) facilitates recovery from renal damage by ameliorating mitochondrial dysfunction induced by folic acid. Front Pharmacol. 2021;12:788977.","journal-title":"Front Pharmacol"},{"key":"4045_CR48","first-page":"6286984","volume":"2020","author":"X Li","year":"2020","unstructured":"Li X, Zou Y, Xing J, et al. Pretreatment with Roxadustat (FG-4592) attenuates folic Acid-Induced kidney injury through antiferroptosis via Akt\/GSK-3beta\/Nrf2 pathway. Oxid Med Cell Longev. 2020;2020:6286984.","journal-title":"Oxid Med Cell Longev"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04045-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:33:17Z","timestamp":1741278797000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04045-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4045"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04045-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethical Committee of Qilu Hospital of Shandong University (Qingdao), the approval number: KYDWLL-201906.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}